# Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

> **NCT03617328** · PHASE1,PHASE2 · COMPLETED · sponsor: **Craig L Slingluff, Jr** · enrollment: 33 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** 6MHP
- **DRUG:** Montanide ISA-51
- **DRUG:** polyICLC
- **DRUG:** CDX-1127

## Key facts

- **NCT ID:** NCT03617328
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2024-01-19
- **Final completion:** 2024-01-19
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03617328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03617328, "Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03617328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*